Also trades as: ACON (NASDAQ) · $vol 0M
ACONW NASDAQ
Aclarion, Inc.
1W: +16.7%
1M: -5.4%
3M: +12.4%
YTD: -19.8%
1Y: -33.6%
3Y: -80.7%
$0.03
+0.00 (+0.67%)
Weekly Expected Move ±64.4%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (15)
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Aclarion, Inc. (NASDAQ:ACON) Sees Large Growth in Short Interest
Aclarion announces $2.5M stock repurchase plan
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Aclarion, Inc. (NASDAQ:ACON) Sees Large Decline in Short Interest
Q1 EPS Estimates for Aclarion Increased by Analyst
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet